- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06453642
Evaluación de una embólica controlada de preparación simple (GPX)
Evaluación de una embólica controlada de preparación simple (ensayo GPX)
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The investigation is a single-arm, open-label, non-randomized, prospective, multicenter, multinational pivotal study. Subjects will undergo distal embolization in the peripheral vasculature, including vascular tumors, renal embolizations, and portal vein branches, with the GPX® Embolic Device and will then be followed 30-days post-procedure.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá, M5B 1W8
- St. Michael's Hospital
-
Toronto, Ontario, Canadá, M5G 1Z5
- Toronto General Hosptial
-
Toronto, Ontario, Canadá, M5G 2C4
- Mount Sinai Hospital Toronto
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92037
- University of California San Diego Altman Clinical and Translation Research Institute
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Anschutz Medical Campus
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University - Barnes Jewish Hospital
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Albany Medical Center
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Estados Unidos, 10029
- Mount Sinai
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- University of North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- Atrium Health Carolinas Medical Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- University of Texas Southwestern
-
Houston, Texas, Estados Unidos, 77030
- MD Anderson Cancer Center - Interventional Radiology
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia Health System
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
-
-
-
-
Auckland, Nueva Zelanda
- Auckland City Hospital
-
Christchurch, Nueva Zelanda, 4710
- Christchurch Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Age ≥18 years on the date of consent
-
Expected post-procedural lifespan of at least 30 days, in the opinion of the investigator, to allow for participation in all follow-up visits
-
Presents with need for peripheral embolization where there is a desire for distal vessel bed penetration including:
- Vascular tumors (e.g., renal angiomyolipoma, renal cell carcinoma, bone tumors, bleeding tumors, and other vascular tumors)
- Renal embolization
- Portal vein branches
-
Informed consent granted by the patient or legally authorized representative
-
Willing and able to comply with the protocol-specified procedures and assessments
Exclusion Criteria:
- Requires embolization for any of the following applications: a) Neurovasculature b) Coronary vasculature c) Hemorrhage due to trauma d) Non-tumoral focal/active bleeding sites (e.g., gastrointestinal tract, urinary tract, lung) e) Veins other than portal vein f) Aneurysms g) Endoleaks h) Vascular malformations i) Vessels for flow redistribution
- Has undergone an embolization procedure within 30 days prior to consent
- Presents with need for embolization where the risk of clinically significant infarction outweighs the benefit of distal penetration (e.g., gastrointestinal, uterine)
- Embolization target is only intended for temporary occlusion (e.g., bioresorbable biologic embolic agents)
- Known allergy or hypersensitivity to contrast media that cannot be adequately medicated
- Pregnant, planning to become pregnant during the study period, or breastfeeding
- Unresolved systemic infection or localized infection in the targeted region
- Pre-operative laboratory tests and/or physical examination indicate abnormal results, which, in the opinion of the investigator, would clinically confound the study primary endpoints
- Existing medical condition which, in the opinion of the investigator, may cause the subject to be intolerant of an occlusion procedure or non-compliant with the protocol or may confound the data interpretation
- Subject is participating in another device, drug, or procedure clinical investigation and has not completed the study treatment or the other investigation clinically interferes with the endpoints of this study (post-approval registries are allowed as long as the investigator determines there is no clinical interference with study endpoints)
- Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults) 12. Patients with drug or alcohol dependency (within 6 months prior to study entry) that, in the opinion of the investigator, would interfere with safe delivery of the study treatment or with the interpretation of study results
Intra-procedural exclusion criteria:
13. Presence of persistent, flow-limiting vasospasm that is not responsive to chemical or mechanical interventions 14. Presence of collateral pathways potentially endangering normal territories during embolization 15. Blood flow precludes safe delivery of embolic material (e.g., arteriovenous shunting or high, unpredictable flow exists) 16. Anatomy that precludes advancement of the delivery device to target vessel embolization site or delivery of embolic material 17. Dissection in the target vessel 18. The delivery device has already been used with an ionic contrast agent (e.g., Conray® (iothalamate meglumine injection USP 60%), Guerbet)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Dispositivo embólico GPX®
|
Treatment includes distal embolization in the peripheral vasculature of vascular tumors, renal embolization, and portal vein branches |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Freedom From Major Adverse Events (MAEs)
Periodo de tiempo: Index procedure through 30-day follow-up
|
MAEs are defined as:
|
Index procedure through 30-day follow-up
|
|
Number of Participants With Successful Delivery of the GPX Embolic Device to the Target Vessel Embolization Site(s)
Periodo de tiempo: During procedure (an average of 1 to 3 hours) after device (GPX) delivery
|
Determined by the investigator during procedure |
During procedure (an average of 1 to 3 hours) after device (GPX) delivery
|
|
Number of Participants With Successful Occlusion of Flow Immediately Beyond the Target Vessel Embolization Site(s)
Periodo de tiempo: End of procedure, an average of 1 to 3 hours
|
Determined by the core lab via comparison of the pre- and final post-embolization images |
End of procedure, an average of 1 to 3 hours
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Number of Participants With Occurrence of Device-related Adverse Events (AE) Through 30 Days Post-index Procedure
Periodo de tiempo: 30-day follow-up
|
30-day follow-up
|
|
Number of Participants With Occurrence of Adjunctive Embolization Agent Usage During the Embolization Procedure
Periodo de tiempo: End of procedure, an average of 1 to 3 hours
|
End of procedure, an average of 1 to 3 hours
|
|
Number of Participants With Occurrence of Catheter Occlusion Due to the GPX Embolic Material
Periodo de tiempo: End of procedure, an average of 1 to 3 hours
|
End of procedure, an average of 1 to 3 hours
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Michael Darcy, MD, Washington University School of Medicine
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades óseas
- Enfermedades musculoesqueléticas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias Urológicas
- Carcinoma
- Neoplasias Renales
- Neoplasias De Tejidos Conectivos Y Blandos
- Neoplasias De Tejido Adiposo
- Neoplasias de células epitelioides perivasculares
- Carcinoma De Célula Renal
- Neoplasias Óseas
- Angiomiolipoma
Otros números de identificación del estudio
- FLX-CL-5000
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .